Microbiota and Human Milk Oligosaccharides in Premature Infants

Area of Science:

• Microbiology
• Neonatology
• Pediatric Nutrition

Background:

• Infant gut microbiota composition is critical for health, with Bifidobacteria linked to lower infection rates in term breastfed infants.
• Limited research exists on microbiota in premature infants, who have distinct gut microbial colonization patterns.
• Human milk oligosaccharides (HMOs) in maternal milk can mitigate the effects of cesarean birth on infant gut microbiota.

Purpose of the Study:

• To investigate the impact of human milk oligosaccharides (HMOs) supplementation on the gut microbiota of premature infants.
• To determine if HMO-enriched formula can promote a gut microbiota profile closer to that of breastfed infants.

Main Methods:

• Observational study of 577 preterm newborns (<32 weeks gestation) to characterize gut microbiota clusters.
• Analysis of microbiota in infants fed formula with and without 2 HMOs.
• Multicenter randomized controlled intervention study to evaluate HMO liquid supplement effects.

Main Results:

• Preterm infant gut microbiota can be classified into six clusters, associated with infant maturity and perinatal factors, impacting outcomes.
• Formula supplemented with 2 HMOs resulted in infant microbiota profiles more similar to breastfed infants compared to standard formula.
• Ongoing analysis of a randomized controlled trial assessing HMO supplementation in premature infants.

Conclusions:

• Preterm infant gut microbiota is complex and not solely Bifidobacteria-driven.
• HMO supplementation in infant formula shows promise for modulating gut microbiota towards a breastfed pattern.
• Further research through intervention studies is needed to confirm the benefits of HMOs for premature infant gut health.